Pages that link to "Q46624747"
Jump to navigation
Jump to search
The following pages link to Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients (Q46624747):
Displaying 50 items.
- Estrogen receptor alpha gene amplification in breast cancer: 25 years of debate (Q24273274) (← links)
- HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors (Q24297102) (← links)
- Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors (Q24644787) (← links)
- Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues (Q24653036) (← links)
- Role of HER2 in NSCLC (Q26781683) (← links)
- Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer? (Q26798882) (← links)
- HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches (Q26866534) (← links)
- Targeted therapies in development for non-small cell lung cancer (Q27022852) (← links)
- Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein (Q27667382) (← links)
- EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer (Q27851583) (← links)
- HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients (Q27852057) (← links)
- Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers (Q27852116) (← links)
- Epidermal growth factor receptor mutations in lung cancer (Q29615474) (← links)
- HER2 expression as a potential marker for response to therapy targeted to the EGFR. (Q33240248) (← links)
- The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target (Q33274011) (← links)
- Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients (Q33290653) (← links)
- Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry (Q33398141) (← links)
- Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines (Q33411775) (← links)
- Gene copy number analysis for family data using semiparametric copula model. (Q33509304) (← links)
- ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics (Q33601653) (← links)
- Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops (Q33769820) (← links)
- The Role of Human Epidermal Growth Factor Receptor 2 as a Prognostic Factor in Lung Cancer: A Meta-Analysis of Published Data (Q33770932) (← links)
- Integrating Epigenomics into Pharmacogenomic Studies (Q33980155) (← links)
- Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance (Q34125003) (← links)
- Lung cancer in never smokers: molecular profiles and therapeutic implications (Q34177155) (← links)
- Allelotypes of lung adenocarcinomas featuring ALK fusion demonstrate fewer onco- and suppressor gene changes (Q34536679) (← links)
- The HER family and cancer: emerging molecular mechanisms and therapeutic targets (Q34558080) (← links)
- Comparing antibody and small-molecule therapies for cancer (Q34560075) (← links)
- ERBB3: Multifunctional enabler or primary actor in pancreatic cancer? (Q34582111) (← links)
- Mutations in epidermal growth factor receptor gene in esophageal squamous cell carcinoma patients in kashmir- a high incidence area of India (Q34747189) (← links)
- Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity. (Q34789161) (← links)
- HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. (Q34942996) (← links)
- Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay (Q35017477) (← links)
- ESR1 amplification in breast cancer by optimized RNase FISH: frequent but low-level and heterogeneous (Q35075706) (← links)
- Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status (Q35137474) (← links)
- Unique FISH Patterns Associated with Cancer Progression of Oral Dysplasia (Q35596552) (← links)
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients (Q35677709) (← links)
- Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer (Q35983929) (← links)
- Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis (Q36040002) (← links)
- EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort (Q36048238) (← links)
- p95HER2 truncated form in resected non-small cell lung cancer (Q36170889) (← links)
- Epidermal Growth Factor (EGFR) copy number aberrations in esophageal and gastro-esophageal junctional carcinoma (Q36172082) (← links)
- Genetic and biochemical alterations in non-small cell lung cancer (Q36184584) (← links)
- Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling (Q36288956) (← links)
- Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (Q36322658) (← links)
- HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation (Q36322762) (← links)
- An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer (Q36327104) (← links)
- Tailor-made chemotherapy for non-small cell lung cancer patients (Q36430761) (← links)
- Recent trends in the treatment of advanced lung cancer (Q36492444) (← links)
- Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations (Q36495936) (← links)